Drug Profile

VY 1706

Alternative Names: tau silencing gene therapy program; VY-1706

Latest Information Update: 16 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Voyager Therapeutics
Class Antidementias; Gene therapies; Small interfering RNA
Mechanism of Action RNA interference; Tau protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Alzheimer's disease

Most Recent Events

13 Jul 2026 Adverse events and pharmacodynamics data from a preclinical trials in Alzheimer's disease released by Voyager
01 Jun 2026 US FDA approves IND application for VY 1706 in Alzheimer’s disease
13 May 2026 Adverse events, pharmacodynamics and pharmacokinetics data from a preclinical trials in Alzheimer's disease released by Voyager

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com